Fc domain effector activity in dengue disease
登革热疾病中的 Fc 结构域效应子活性
基本信息
- 批准号:10386779
- 负责人:
- 金额:$ 41.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesAntibody-Dependent EnhancementAntigenic SpecificityAreaBlood PlateletsBlood VesselsCell LineCessation of lifeCharacteristicsClinicalComplexDengueDengue FeverDengue Hemorrhagic FeverDengue InfectionDiseaseDisease susceptibilityEngineeringExhibitsExtravasationFamilyFc domainFeverFlavivirusFlavivirus InfectionsHemorrhagic ShockHumanHuman ActivitiesIgG1ImmuneImmune responseImmunityImmunoglobulin GIn VitroIndividualInfectionInflammatoryInfluenza vaccinationLeukocytesLifeMediatingModelingMonoclonal AntibodiesMorbidity - disease ratePathogenesisPathogenicityPathologyPathway interactionsPatientsPolysaccharidesPopulationPredispositionPrimary InfectionPublic HealthRecording of previous eventsRisk FactorsRoleSeroprevalencesSeveritiesSeverity of illnessShockStructureSymptomsSyndromeTestingThrombocytopeniaVaccinesVariantVirusWest Nile virusYellow FeverZIKAbaseclinical phenotypecohortcross reactivityepidemiologic dataepidemiology studyfollow-uphigh riskhumanized mouseimmunoregulationin vivoinsightmouse modelnovelpreventreceptorresponsesevere denguesocioeconomicsuptakevaccine response
项目摘要
ABSTRACT – Project 1, Ravetch
Flaviviruses, such as dengue, Zika, and West Nile have a significant impact on public health with tremendous
socioeconomic consequences for a large fraction of the world's population. A feature common to all flaviviruses
is the clear distinction between infection and disease. For example, only a small fraction of dengue-infected
individuals develops dengue disease, which is characterized by a diverse spectrum of clinical symptoms of
variable severity. A large body of epidemiological data suggests that prior flavivirus infection represents the major
risk factor for dengue disease susceptibility. Indeed, susceptibility to severe dengue disease is associated with
the titers of cross-reactive, non-neutralizing IgG antibodies that are elicited during primary infection with other
flaviviruses. The established mechanistic model by which IgG antibodies contribute to disease susceptibility is
based upon the in vitro observation that these antibodies mediate infection of leukocytes through increased
uptake of virus-IgG complexes via specific interactions of their Fc domains with Fcγ receptors (FcγRs); a
phenomenon termed antibody-dependent enhancement (ADE) of infection. Although this model can sufficiently
explain susceptibility to dengue disease, it is likely that complex host susceptibility factors exist that contribute
to disease pathogenesis and determine severity among symptomatic dengue patients. Consistent with this
hypothesis, our recent analysis of the Fc domain structure of IgG antibodies derived from dengue patients with
variable disease severity revealed that specific Fc domain characteristics that confer increased affinity for pro-
inflammatory, activating FcγRs, are enriched in patients with severe disease and evidence for specific clinical
manifestations, including thrombocytopenia and vascular leakage. These antibodies exacerbate disease severity
by inducing platelet depletion via FcγR-mediated mechanisms, suggesting that previously-uncharacterized ADE
mechanisms contribute to disease pathology. Understanding the mechanisms that mediate dengue ADE is
essential for predicting the susceptibility to severe dengue disease in high-risk patient groups and developing
approaches to prevent or reduce disease-associated clinical manifestations. In the proposed studies, we will
analyze the IgG responses from cohorts of dengue-infected patients with variable disease severity to identify the
specific IgG features that are associated with dengue disease severity and clinical manifestations. Follow-up
mechanistic studies in mouse models of dengue disease using strains fully humanized for all classes of FcγRs
will be performed to determine the role of specific human FcγRs in dengue disease and characterize the precise
FcγR pathways that contribute to disease pathogenesis. Lastly, we will characterize IgG responses elicited upon
influenza vaccination of individuals with differential susceptibility to severe flavivirus infection to determine
whether changes in the Fc domain structure represent immune determinants for predicting disease susceptibility.
Our studies will provide novel insights into the mechanisms by which pathogenic IgG antibodies mediate dengue
disease and have a broader impact on our understanding of the pathogenesis of other flaviviruses, like Zika.
摘要-项目1,Ravetch
黄病毒,如登革热、寨卡病毒和西尼罗河病毒,对公众健康有重大影响,
对世界上很大一部分人口的社会经济影响。所有黄病毒的共同特征
是感染和疾病之间的明显区别。例如,只有一小部分感染登革热的人
个人患上登革热,其特征是临床症状多种多样
严重程度可变。大量的流行病学数据表明,先前的黄病毒感染是主要的
登革热易感性的危险因素。事实上,对严重登革热的易感性与
在与其他人初次感染期间产生的交叉反应、非中和抗体滴度
黄病毒。已建立的免疫球蛋白抗体促进疾病易感性的机制模型是
根据体外观察,这些抗体通过增加
通过其Fc结构域与Fcγ受体(FcγR)的特异性相互作用摄取病毒免疫球蛋白复合体;a
这种现象被称为抗体依赖的感染增强(ADE)。尽管该模型可以充分地
解释登革热的易感性,很可能存在复杂的宿主易感因素
以确定有症状的登革热患者的疾病发病机制和严重程度。与此一致
假设,我们最近对来自登革热患者的免疫球蛋白抗体Fc区结构的分析
不同的疾病严重程度表明,特定的Fc结构域特征,赋予增加亲和力-
炎症,激活Fcγ受体,在重症患者中丰富,并为特定的临床证据
临床表现包括血小板减少和血管渗漏。这些抗体加重了疾病的严重性。
通过FcγR介导的机制诱导血小板耗竭,表明以前未描述的ADE
机制对疾病病理有贡献。了解介导登革热ADE的机制是
对预测高危人群中严重登革热的易感性和发展至关重要
预防或减少疾病相关临床表现的方法。在建议的研究中,我们会
分析不同疾病严重程度的登革热感染患者的免疫球蛋白反应,以确定
与登革热严重程度和临床表现相关的特异性免疫球蛋白特征。跟进
所有Fc-γ受体完全人源化菌株在登革热小鼠模型中的机制研究
将被用来确定特定的人类Fcγ受体在登革热疾病中的作用,并表征准确的
参与疾病发病机制的Fc-γ-R通路。最后,我们将描述在以下情况下引发的免疫球蛋白反应
流感疫苗接种对严重黄病毒感染易感性不同个体的确定
Fc结构域结构的变化是否代表预测疾病易感性的免疫决定因素。
我们的研究将为致病免疫球蛋白抗体介导登革热的机制提供新的见解。
并对我们了解寨卡病毒等其他黄病毒的发病机制产生了更广泛的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY Victor RAVETCH其他文献
JEFFREY Victor RAVETCH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY Victor RAVETCH', 18)}}的其他基金
Integrating innate and adaptive pathways in vaccine responses
将先天和适应性途径整合到疫苗反应中
- 批准号:
10265794 - 财政年份:2020
- 资助金额:
$ 41.75万 - 项目类别:
Molecular mechanisms of antibody-mediated immunotherapies
抗体介导的免疫疗法的分子机制
- 批准号:
10368931 - 财政年份:2016
- 资助金额:
$ 41.75万 - 项目类别:
Molecular mechanisms of antibody-mediated immunotherapies
抗体介导的免疫疗法的分子机制
- 批准号:
10684073 - 财政年份:2016
- 资助金额:
$ 41.75万 - 项目类别:
Molecular mechanisms of antibody-mediated immunotherapies
抗体介导的免疫疗法的分子机制
- 批准号:
8940844 - 财政年份:2016
- 资助金额:
$ 41.75万 - 项目类别:
Molecular mechanisms of antibody-mediated immunotherapies
抗体介导的免疫疗法的分子机制
- 批准号:
10518790 - 财政年份:2016
- 资助金额:
$ 41.75万 - 项目类别:
Molecular mechanisms of antibody-mediated immunotherapies
抗体介导的免疫疗法的分子机制
- 批准号:
9888968 - 财政年份:2016
- 资助金额:
$ 41.75万 - 项目类别:
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain
通过修饰 Fc 结构域增强 MUC16 定向抗体的功效
- 批准号:
8933343 - 财政年份:2015
- 资助金额:
$ 41.75万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 41.75万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 41.75万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 41.75万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 41.75万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 41.75万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 41.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 41.75万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 41.75万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 41.75万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 41.75万 - 项目类别: